

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Previously Presented) A method for impairing cumulus expansion and oocyte maturation, comprising antagonizing the EP₂ receptor and inhibiting cyclooxygenase COX-2.

Claim 2. (Previously Presented) The method of claim 1, comprising antagonizing the EP₂ receptor by the EP₂ receptor antagonist AH6809.

Claim 3. (Previously Presented) The method of claim 1, comprising administering a composition comprising an EP₂ receptor antagonist and at least one COX inhibitor.

Claim 4. (Previously Presented) A method of fertility control in a woman comprising administering an EP₂ receptor antagonist and a cyclooxygenase COX-2 inhibitor.

Claim 5. (Previously Presented) The method according to claim 4, comprising administering an EP₂ receptor antagonist.

Claim 6. (Previously Presented) The method according to claim 4, comprising administering a composition comprising an EP₂ receptor antagonist and at least one COX inhibitor.

Claim 7. (Previously Presented) The method according to claim 6, wherein said COX inhibitor is selective for cyclooxygenase-2 (COX-2).

Claim 8. (Previously Presented) The method according to claim 6 wherein the COX inhibitor is Celecoxib, Ceracoxib, Parecoxib, Rofecoxib, Valdecoxib, NS-398 or Etoricoxib.

Claim 9. (Previously Presented) The method according to claim 6 wherein the COX inhibitor is Celecoxib or Rofecoxib.

Claim 10. (Previously Presented) The method according to claim 6 comprising administering said composition orally.

Claim 11. (Previously Presented) The method of claim 1 for achieving fertility control in a woman.

Claim 12. (Previously Presented) The method according to claim 4, comprising antagonizing the EP₂ receptor by the EP₂ receptor antagonist AH6809.

Claim 13. (Previously Presented) The method according to claim 3 comprising administering the EP₂ receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib, Ceracoxib, Parecoxib, Rofecoxib, Valdecoxib, NS-398 or Etoricoxib.

Claim 14. (Previously Presented) The method according to claim 6 comprising administering the EP₂ receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib, Ceracoxib, Parecoxib, Rofecoxib, Valdecoxib, NS-398 or Etoricoxib.

Claim 15. (Previously Presented) The method according to claim 3 comprising administering the EP₂ receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib or Rofecoxib.

Claim 16. (Previously Presented) The method according to claim 6 comprising administering the EP₂ receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib or Rofecoxib.

Claim 17. (Previously Presented) A method for impairing cumulus expansion and oocyte maturation comprising antagonizing the EP₂ receptor with an EP₂ receptor antagonist and inhibiting cyclooxygenase COX-2 with a Cox-2 inhibitor.

Claim 18. (Previously Presented) The method according to claim 17, wherein said EP₂ receptor antagonist is selective for said EP₂ receptor and said Cox-2 inhibitor is selective for said Cox-2.